Neurogene Inc. Share Price & Technical Analysis
NGNE · $27.71 (+0.36%)
Healthcare / Biotechnology
$27.71
+0.36%
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten diseas…
Price chart
Seasonality
May has 3 positive and 2 negative years (last 5 years shown)
7% return in May, 4% avg return in past 3 year May month.
42% return in 2026, 71% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | -14% | 34% | -14% | 29% | 7% | – | – | – | – | – | – | – | 42% |
| 25 | -32% | 16% | -34% | 27% | 13% | -14% | 41% | -13% | -6% | 98% | -32% | -1% | 63% |
| 24 | 56% | 5% | 63% | -32% | 10% | -4% | 13% | -9% | 13% | 6% | -43% | -9% | 68% |
| 23 | 21% | -17% | 35% | 30% | -11% | 2% | -14% | 11% | 4% | -15% | -5% | 41% | 83% |
| 22 | -27% | -28% | -28% | -35% | -17% | -2% | -2% | 2% | -39% | -16% | -9% | 2% | -198% |
Monthly return % by calendar month · historical pattern, not a forecast
Weak · Uptrend · Uptrend
Neurogene Inc., a clinical stage biotechnology company, develops genetic medicines for rare neurological diseases. The company's product candidates include NGN-401 that is packaged in an adeno-associated virus 9, which is in Phase 1/2 clinical trial for the treatment of Rett syndrome; and NGN-101, a conventional gene therapy candidate that is in Phase 1/2 clinical trial to treat CLN5 Batten disease. It has a license agreement with The University of Edinburgh, Virovek, Inc., Sigma-Aldrich Co. LLC., and Leland Stanford Junior University. The company was founded in 2018 and is headquartered in New York, New York.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$478.00M
P/E ratio
—
52W high
$37.27
52W low
$14.65
Volume
1,05,384
Beta
2.08
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is Neurogene Inc. share price today?
- Neurogene Inc. (NGNE) last traded around $27.71 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does NGNE have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for NGNE. Download the app for real-time alerts.
- How can I analyze Neurogene Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.